Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis

Matteo Fassan, Marco Pizzi, Giorgio Battaglia, Luciano Giacomelli, Paola Parente, Paolo Bocus, Ermanno Ancona, Massimo Rugge

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Aim: To test the contribution of programmed cell death 4 (PDCD4) tumour suppressor gene in Barrett's carcinogenesis. Methods: PDCD4 immunohistochemical expression was assessed in 88 biopsy samples obtained from histologically proven long-segment Barrett's mucosa (BM; 25 non-intestinal columnar metaplasia, 25 intestinal metaplasia (IM), 16 low-grade intraepithelial neoplasia (LG-IEN), 12 high-grade IEN (HG-IEN) and 10 Barrett's adenocarcinoma (BAc)). As controls, 25 additional samples of native oesophageal mucosa (N) were obtained from patients with dyspepsia. To further support the data, the expression levels of miR-21, an important PDCD4 expression regulator, in 14 N, 5 HG-IEN and 11 BAc samples were determined by quantitative real-time PCR analysis. Results: PDCD4 immunostaining decreased progressively and significantly with the progression of the phenotypic changes occurring during Barrett's carcinogenesis (p

Original languageEnglish
Pages (from-to)692-696
Number of pages5
JournalJournal of Clinical Pathology
Volume63
Issue number8
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Carcinogenesis
Cell Death
Metaplasia
Adenocarcinoma
Dyspepsia
Tumor Suppressor Genes
Real-Time Polymerase Chain Reaction
Mucous Membrane
Biopsy
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Fassan, M., Pizzi, M., Battaglia, G., Giacomelli, L., Parente, P., Bocus, P., ... Rugge, M. (2010). Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. Journal of Clinical Pathology, 63(8), 692-696. https://doi.org/10.1136/jcp.2010.078253

Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. / Fassan, Matteo; Pizzi, Marco; Battaglia, Giorgio; Giacomelli, Luciano; Parente, Paola; Bocus, Paolo; Ancona, Ermanno; Rugge, Massimo.

In: Journal of Clinical Pathology, Vol. 63, No. 8, 08.2010, p. 692-696.

Research output: Contribution to journalArticle

Fassan, M, Pizzi, M, Battaglia, G, Giacomelli, L, Parente, P, Bocus, P, Ancona, E & Rugge, M 2010, 'Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis', Journal of Clinical Pathology, vol. 63, no. 8, pp. 692-696. https://doi.org/10.1136/jcp.2010.078253
Fassan, Matteo ; Pizzi, Marco ; Battaglia, Giorgio ; Giacomelli, Luciano ; Parente, Paola ; Bocus, Paolo ; Ancona, Ermanno ; Rugge, Massimo. / Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. In: Journal of Clinical Pathology. 2010 ; Vol. 63, No. 8. pp. 692-696.
@article{b50ac49c9d3c48a698f038eda0526f45,
title = "Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis",
abstract = "Aim: To test the contribution of programmed cell death 4 (PDCD4) tumour suppressor gene in Barrett's carcinogenesis. Methods: PDCD4 immunohistochemical expression was assessed in 88 biopsy samples obtained from histologically proven long-segment Barrett's mucosa (BM; 25 non-intestinal columnar metaplasia, 25 intestinal metaplasia (IM), 16 low-grade intraepithelial neoplasia (LG-IEN), 12 high-grade IEN (HG-IEN) and 10 Barrett's adenocarcinoma (BAc)). As controls, 25 additional samples of native oesophageal mucosa (N) were obtained from patients with dyspepsia. To further support the data, the expression levels of miR-21, an important PDCD4 expression regulator, in 14 N, 5 HG-IEN and 11 BAc samples were determined by quantitative real-time PCR analysis. Results: PDCD4 immunostaining decreased progressively and significantly with the progression of the phenotypic changes occurring during Barrett's carcinogenesis (p",
author = "Matteo Fassan and Marco Pizzi and Giorgio Battaglia and Luciano Giacomelli and Paola Parente and Paolo Bocus and Ermanno Ancona and Massimo Rugge",
year = "2010",
month = "8",
doi = "10.1136/jcp.2010.078253",
language = "English",
volume = "63",
pages = "692--696",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis

AU - Fassan, Matteo

AU - Pizzi, Marco

AU - Battaglia, Giorgio

AU - Giacomelli, Luciano

AU - Parente, Paola

AU - Bocus, Paolo

AU - Ancona, Ermanno

AU - Rugge, Massimo

PY - 2010/8

Y1 - 2010/8

N2 - Aim: To test the contribution of programmed cell death 4 (PDCD4) tumour suppressor gene in Barrett's carcinogenesis. Methods: PDCD4 immunohistochemical expression was assessed in 88 biopsy samples obtained from histologically proven long-segment Barrett's mucosa (BM; 25 non-intestinal columnar metaplasia, 25 intestinal metaplasia (IM), 16 low-grade intraepithelial neoplasia (LG-IEN), 12 high-grade IEN (HG-IEN) and 10 Barrett's adenocarcinoma (BAc)). As controls, 25 additional samples of native oesophageal mucosa (N) were obtained from patients with dyspepsia. To further support the data, the expression levels of miR-21, an important PDCD4 expression regulator, in 14 N, 5 HG-IEN and 11 BAc samples were determined by quantitative real-time PCR analysis. Results: PDCD4 immunostaining decreased progressively and significantly with the progression of the phenotypic changes occurring during Barrett's carcinogenesis (p

AB - Aim: To test the contribution of programmed cell death 4 (PDCD4) tumour suppressor gene in Barrett's carcinogenesis. Methods: PDCD4 immunohistochemical expression was assessed in 88 biopsy samples obtained from histologically proven long-segment Barrett's mucosa (BM; 25 non-intestinal columnar metaplasia, 25 intestinal metaplasia (IM), 16 low-grade intraepithelial neoplasia (LG-IEN), 12 high-grade IEN (HG-IEN) and 10 Barrett's adenocarcinoma (BAc)). As controls, 25 additional samples of native oesophageal mucosa (N) were obtained from patients with dyspepsia. To further support the data, the expression levels of miR-21, an important PDCD4 expression regulator, in 14 N, 5 HG-IEN and 11 BAc samples were determined by quantitative real-time PCR analysis. Results: PDCD4 immunostaining decreased progressively and significantly with the progression of the phenotypic changes occurring during Barrett's carcinogenesis (p

UR - http://www.scopus.com/inward/record.url?scp=77955733831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955733831&partnerID=8YFLogxK

U2 - 10.1136/jcp.2010.078253

DO - 10.1136/jcp.2010.078253

M3 - Article

VL - 63

SP - 692

EP - 696

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 8

ER -